A Multicenter, Prospective, Biomarker-result-blinded Observational Study Evaluating Immunoassay Measurements of Pancreatic Stone Protein Performed on Abionic's abioSCOPE Device with the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying

Grants and Contracts Details

StatusFinished
Effective start/end date8/4/208/3/22

Funding

  • Abionic SA: $56,593.00